NewsRoom Articles - Page 722 of 1421

TuesdayOct 29, 2019 4:30 pm

BioCardia (NASDAQ: BCDA) Starts Presentation at Dawson James Small Cap Growth Conference

BioCardia (NASDAQ: BCDA) is developing regenerative biologic therapies to treat cardiovascular disease. CardiAMP™ and CardiALLO™ cell therapies are the company's biotherapeutic product candidates in clinical development. BioCardia's current products include the Helix™ Biotherapeutic Delivery System and the Morph® steerable guide and sheath catheter portfolio, including the new AVANCE™ Steerable Introducer family. BioCardia also partners with other biotherapeutic companies to provide its Helix systems and clinical support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction. For more information, visit the company's website at www.biocardia.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news…

TuesdayOct 29, 2019 4:05 pm

DelMar Pharmaceuticals Inc. (NASDAQ: DMPI) Starts Presentation at Dawson James Small Cap Growth Conference

DelMar Pharmaceuticals (NASDAQ: DMPI) concentrates on the development and commercialization of new therapies for cancer patients who have limited or no treatment options. Focused on understanding tumor biology and mechanisms of treatment resistance, DelMar identifies biomarkers to personalize new therapies in indications where patients are failing, or are unable to tolerate, standard-of-care treatments. The company's current pipeline is based around VAL-083, a "first-in-class", small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers including central nervous system, ovarian and other solid tumors in U.S. clinical trials sponsored by the NCI. Delmar is…

TuesdayOct 29, 2019 4:05 pm

Lineage Cell Therapeutics Inc. (NYSE: LCTX) Starts Presentation at Dawson James Small Cap Growth Conference

Lineage Cell Therapeutics (NYSE: LCTX) is a clinical-stage biotech company developing novel cell therapies for unmet medical needs. The company's programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. Utilizing its unique platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage is developing three cell…

TuesdayOct 29, 2019 3:40 pm

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) Starts Presentation at Dawson James Small Cap Growth Conference

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) is a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases such as ALS, Multiple Sclerosis and Parkinson's Disease. BrainStorm holds the exclusive worldwide rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. FDA and the European Medicines Agency in ALS. BrainStorm is currently enrolling a phase 3 pivotal trial in ALS, investigating repeat-administration of autologous MSC-NTF cells. The pivotal study is intended to support a filing for U.S. FDA approval…

TuesdayOct 29, 2019 3:40 pm

BeyondSpring Inc. (NASDAQ: BYSI) Starts Presentation at Dawson James Small Cap Growth Conference

BeyondSpring (NASDAQ: BYSI) is a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies. BeyondSpring employs a novel, scalable business model that integrates U.S. and Chinese clinical resources, aimed at creating maximum value for all stakeholders. BeyondSpring also intends to pursue internal development and selective acquisitions of pharmaceutical products with a clear, near-term pathway to global approvals. BeyondSpring has a robust drug development pipeline at various clinical and pre-clinical stages. The company's lead asset, Plinabulin, is in a phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC)…

TuesdayOct 29, 2019 3:15 pm

Dare Bioscience Inc. (NASDAQ: DARE) Starts Presentation at Dawson James Small Cap Growth Conference

Dare Bioscience (NASDAQ: DARE) is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's sexual health, vaginal health, fertility and contraception. The company is identifying, developing and bringing to market a portfolio of novel, differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women's health. Dare's product portfolio includes potential first-in-class candidates in clinical development: Ovaprene, a non-hormonal, monthly contraceptive vaginal ring; and Sildenafil Cream, a potential treatment for female sexual arousal disorder, as well as a proprietary solution-to-gel formulation of clindamycin to treat bacterial vaginosis via a single application. For more information,…

TuesdayOct 29, 2019 3:15 pm

Todos Medical Ltd. (TOMDF) Starts Presentation at Dawson James Small Cap Growth Conference

Todos Medical Ltd. (OTCQB: TOMDF) is an in-vitro diagnostic company engaged in the development of blood tests for the early detection of a variety of cancers. The company also has initiated the development of blood tests for neurodegenerative disorders such as Alzheimer's disease through Breakthrough Diagnostics Inc., its joint venture with Amarantus Bioscience Holdings Inc. Todos has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancer's influence on the immune system, which triggers biochemical changes in peripheral blood mononuclear…

TuesdayOct 29, 2019 2:50 pm

Orgenesis Inc. (NASDAQ: ORGS) Starts Presentation at Dawson James Small Cap Growth Conference

Orgenesis (NASDAQ: ORGS) is a vertically integrated biopharmaceutical company specializing in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. Through its subsidiary, MaSTherCell, Orgenesis delivers optimized process industrialization capacities to cell therapy companies and speeds the arrival of these therapies to market. MaSTherCell's customers include many of the world's leading pharmaceutical and biotech companies, as well as research institutions and hospitals involved in cutting edge cell therapy. Orgenesis is also developing its own propriety cell therapies and is a pioneer in the process of trans-differentiation (cell reprograming). Orgenesis has utilized its proprietary…

TuesdayOct 29, 2019 2:50 pm

Check-Cap Ltd. (NASDAQ: CHEK) Starts Presentation at Dawson James Small Cap Growth Conference

Check-Cap (NASDAQ: CHEK) (NASDAQ: CHEKW) (NASDAQ: CHEKZ) is advancing the development of the C-Scan® System, the first and only preparation-free ingestible scanning capsule-based system for the prevention of colorectal cancer ("CRC") through the detection of precancerous polyps. The patient-friendly test has the potential to increase screening adherence and reduce the overall incidence of CRC. The C-Scan® System utilizes an ultra-low dose X-ray capsule, an integrated positioning, control, and recording system, as well as proprietary software to generate a 3D map of the inner lining of the colon. The C-Scan® System is non-invasive and requires no preparation or sedation, allowing patients…

TuesdayOct 29, 2019 2:25 pm

Athersys Inc. (NASDAQ: ATHX) Starts Presentation at Dawson James Small Cap Growth Conference

Athersys (NASDAQ: ATHX) is working to change the future of medicine. A clinical-stage biotechnology company, Athersys is developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life. With a focus on developing therapies in regenerative medicine, Athersys is developing therapeutic products the company believes have best-in-class potential. The company's lead platform product, MultiStem cell therapy, has shown promise for treating indications in the neurological, inflammatory and immune, and cardiovascular disease areas. Its most advanced program focused on the treatment of ischemic stroke is in a phase 3 clinical trial. Athersys' wide ranging clinical development…

Financial news and publishing for public and private companies

Contact us: 512.354.7000